Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the cases of two children with treatment-resistant epilepsy (Case A with left frontal dysplasia and Case B with Dravet Syndrome) with initial symptom improvement after the introduction of CBD extracts followed by seizure worsening after a short time. The children presented typical signs of intoxication by Δ9-THC (inappropriate laughter, ataxia, reduced attention, and eye redness) after using a CBD-enriched extract. The extract was replaced by the same dose of purified CBD with no Δ9-THC in both cases, which led to improvement in intoxication signs and seizure remission. These cases support pre-clinical and preliminary clinical evidence suggesting that CBD may be effective for some patients with epilepsy. Moreover, the cases highlight the need for randomized clinical trials using high-quality and reliable substances to ascertain the safety and efficacy of cannabinoids as medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 2×
“…of anandamide, increases hippocampal neurogenesis, interacts with 5HT1A and TRPV1 receptors, and presents antioxidant and neuroprotective effects which may, at least in part, help to explain its anticonvulsant profile (Reif et al., 2007; Zuardi, 2008; Campos and Guimarães, 2008; Wolf et al., 2010).”
BackgroundCampos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · cited 2×
“…of anandamide, increases hippocampal neurogenesis, interacts with 5HT1A and TRPV1 receptors, and presents antioxidant and neuroprotective effects which may, at least in part, help to explain its anticonvulsant profile (Reif et al., 2007; Zuardi, 2008; Campos and Guimarães, 2008; Wolf et al., 2010).”
BackgroundWolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208
Cited by
Labeling Accuracy of Cannabidiol Extracts Sold Online
Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017) · JAMA · doi:10.1001/jama.2017.11909 · Cited by 529
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
Self-citationZuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294
Self-citationA new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis
Berman, P., Futoran, K., Lewitus, G. M., Mukha, D., Benami, M., Shlomi, T., & Meiri, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-32651-4 · Cited by 292
Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00759 · Cited by 190
A Conversion of oral cannabidiol to delta9-tetrahydrocannabinol seems not to occur in humans
Nahler, G., Grotenhermen, F., Zuardi, A. W., & Crippa, J. A. S. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2017.0009 · Cited by 61
Self-citation
Metadata
- Authors
- Crippa, J. A. S., Crippa, A. C. S., Hallak, J. E. C., Martín-Santos, R., & Zuardi, A. W.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2016-09-30
- Volume
- 7
- Pages
- 359-359
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2525028860
- Cited by
- 70
- References
- 6
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.